“We have made the very difficult decision to discontinue some research projects to focus on programs where our innovation and investments may be best positioned to deliver high-impact breakthrough medicines and vaccines,” a Pfizer spokesperson told Becker’s.
The company noted that there may be opportunities for some employees to transition to new roles created within the company.
